Health Care & Life Sciences » Pharmaceuticals | Kaken Pharmaceutical Co. Ltd.

Kaken Pharmaceutical Co. Ltd. | Mutual Funds

Mutual Funds that own Kaken Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Government Pension Fund - Global (The)
998,999
2.06%
411,499
0.01%
12/31/2017
AZ Multi Asset - Institutional T
750,000
1.55%
96,400
1.22%
06/30/2017
Nomura Asset TOPIX ETF Fund (1306)
569,900
1.18%
9,000
0.04%
07/31/2018
Vanguard Total International Stock Index Fund
499,581
1.03%
10,100
0.01%
07/31/2018
Tokio Marine Asset High Yield Low Volatility Jp. Eq. Mother
303,000
0.63%
178,000
1.77%
07/24/2017
Daiwa Asset TOPIX Listed ETF (1305)
279,700
0.57%
4,700
0.04%
07/31/2018
Nikko Asset Listed Index TOPIX ETF (1308)
256,700
0.53%
0
0.04%
08/20/2018
Vanguard Developed Markets Index Fund
196,389
0.41%
-400
0.01%
07/31/2018
Nordea 1 - Stable Return Fund
178,500
0.37%
-77,100
0.05%
07/31/2018
Transamerica International Small Cap Value Fund
152,200
0.31%
5,300
0.9%
01/31/2018

About Kaken Pharmaceutical Co.

View Profile
Address
2-28-8 Honkomagome
Tokyo Tokyo 113
Japan
Employees -
Website http://www.kaken.co.jp
Updated 07/08/2019
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the following business divisions: Pharmaceuticals and Medical Devices, Agrochemicals and Animal Health Products, Overseas Activity, Research & Development, and Licensing Opportunities. The Pharmaceuticals and Medical Devices division offers artz(anti-osteoarthritis), clenafin (topical onychomycosis treatment product), seprafilm (anti-adhesive absorbent barrier), lipidil (anti-hyperlipidemia product), fiblast spray (wound-healing product), mentax (anti-trichophyton product) and generic drugs.